Chuikyo Approves Pfizer’s Selzentry And Janssen Pharma’s Intelence For NHI Listing
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Medical Social Insurance Association (Chuikyo) approved Jan. 14 and listed the price for two HIV antiviral drugs, Pfizer's Selzentry (maraviroc) and Janssen Pharma's Intelence (etravirine). For maraviroc, indicated to treat patients with CCR5-tropic HIV-1 detectable who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents, Chuikyo set the price of ¥2,278.80 per tablet. Designated as an orphan drug, etravirine 100mg was set at ¥619.8 per tablet and a one-day dosage expense of ¥2,478.20. (Click here for more - Japanese language